• Policy
• Negotiations on the Brukinsa price have begun
• by Lee, Tak-Sun Feb 28, 2023 05:52am

• Policy
• The value of pharmaceutical bio innovation is reflected
• by Lee, Jeong-Hwan Feb 24, 2023 05:53am

• Policy
• Expansion of insurance coverage for diabetes drugs
• by Lee, Tak-Sun Feb 24, 2023 05:52am

• Policy
• Daewoong also enter the Vemlidy late-stage drug market
• by Lee, Tak-Sun Feb 23, 2023 05:46am

• Policy
• 9 bepotastine besilate antihistamines listed for reimb
• by Lee, Tak-Sun Feb 23, 2023 05:46am

• Policy
• SGLT-2 DM Combi Benefit Expansion Expected to be applied
• by Lee, Tak-Sun Feb 23, 2023 05:45am

• Policy
• The ruling party promotes the establishment of a serious dz
• by Lee, Jeong-Hwan Feb 22, 2023 05:54am

• Policy
• Lucentis biosimilar Ameliebou prices cut 24.5% voluntarily
• by Kim, Jung-Ju Feb 22, 2023 05:54am

• Policy
• Chong Kun Dang's Tamivir is listed as the lowest price
• by Lee, Tak-Sun Feb 22, 2023 05:54am

• Policy
• Revlimid generics also allowed reimb for MDS
• by Lee, Tak-Sun Feb 22, 2023 05:54am